Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long when when it's put to work in game-changing businesses with well-defined catalysts. 
Via The Motley Fool
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations. 
Via Benzinga
NYSE:JNJ, an undervalued stock with good fundamentals.
JOHNSON & JOHNSON (NYSE:JNJ) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Market Analysis: Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson
Via Benzinga
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
Uncovering Dividend Opportunities with NYSE:JNJ.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
From Beasley Allen
Via Business Wire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
The 7 Best Under $20 Stocks to Buy in June 2024
Stocks may be ready to rally, here are seven of the best under $20 stocks to buy for those who still want value. 
Via InvestorPlace
Blue-Chip Jackpots: 3 Top-Notch Stocks at Bottom-Barrel Prices
Discover three beaten-down blue-chip stocks, including Johnson & Johnson, McDonald's and Accenture, with upside potential. 
Via InvestorPlace
Payout Powerhouses: 7 Dividend Stocks to Buy Now
Although growth ideas will probably always attract the market’s attention, it’s useful to balance your holdings with dividend stocks to buy. 
Via InvestorPlace
Dividend Heaven: 7 Standout Stocks for Income Investors to Buy in June
Here are three dividend stocks to buy for your retirement portfolio that should offer rising income beyond the rate of inflation. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy
From Beasley Allen Law Firm
Via Business Wire
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Johnson & Johnson To Pay $700M To Settle Multi-State Talc Investigation
Although the settlement has been reached, Johnson & Johnson still faces a substantial number of talc-related lawsuits. 
Via Benzinga
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
The integration of AI and healthcare is well underway. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Stocks You Can Safely Hold for the Long Haul
Some services will always be in high demand. 
Via The Motley Fool
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Dive into the fundamentals behind the resilience of recession-proof stocks and the performance indicators driving their success. 
Via InvestorPlace
The 3 Most Undervalued Robinhood Stocks to Buy in June 2024
These three undervalued Robinhood stocks show the platform's users are much more conventional than critics believe. 
Via InvestorPlace
Time to Pounce: 2 High-Yielding Dow Stocks That Are Begging to Be Bought Right Now
Among the Dow's 30 components are two high-octane income stocks that have increased their respective payouts for 37 and 62 consecutive years. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity. 
Via InvestorPlace
3 Stocks to Buy With 20% Upside
All three of these high-quality companies have great upside. 
Via The Motley Fool
The 3 Best Dow Stocks to Buy in June 2024
Discover the three best Dow stocks to buy in June 2024. Invest in these top-performing companies with strong fundamentals. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.